combisyn stungulyf, dreifa 14,0/3,5 % w/v
norbrook laboratories (ireland) limited - amoxicillinum tríhýdrat; acidum clavulanicum kalíum - stungulyf, dreifa - 14,0/3,5 % w/v
combisyn tafla 250 mg
norbrook laboratories (ireland) limited - amoxicillinum tríhýdrat; acidum clavulanicum kalíum - tafla - 250 mg
combisyn tafla 50 mg
norbrook laboratories (ireland) limited - amoxicillinum tríhýdrat; acidum clavulanicum kalíum - tafla - 50 mg
meropenem sun stungulyfs-/innrennslisstofn, lausn 1 g
sun pharmaceutical industries europe b.v. - meropenemum tríhýdrat - stungulyfs-/innrennslisstofn, lausn - 1 g
meropenem sun stungulyfs-/innrennslisstofn, lausn 500 mg
sun pharmaceutical industries europe b.v. - meropenemum tríhýdrat - stungulyfs-/innrennslisstofn, lausn - 500 mg
doribax
janssen-cilag international nv - doripenem - pneumonia, ventilator-associated; pneumonia, bacterial; urinary tract infections; bacterial infections; cross infection - sýklalyf fyrir almenn nota, - doribax er ætlað fyrir meðferð eftirfarandi sýkingum í fullorðnir:sjúkrahúsi, keypti lungnabólgu (þar á meðal öndunarvél-í tengslum lungnabólgu);flókið kviðarholi sýkingum;flókið þvagfærasýkingar. Íhuga ætti að opinbera leiðsögn á réttri notkun af sýklalyfjum.
amoxicillin sandoz mixtúruduft, dreifa 100 mg/ml
sandoz a/s* - amoxicillinum tríhýdrat - mixtúruduft, dreifa - 100 mg/ml
vancomycin-mip innrennslisstofn, lausn 1000 mg
mip pharma gmbh - vancomycin hydrochloride - innrennslisstofn, lausn - 1000 mg
vancomycin-mip innrennslisstofn, lausn 500 mg
mip pharma gmbh - vancomycin hydrochloride - innrennslisstofn, lausn - 500 mg
recarbrio
merck sharp & dohme b.v. - imipenem einhýdrat, cílastatín járn, relebactam einhýdrat - gramm-neikvæð bakteríusýkingum - carbapenems, antibacterials for systemic use, - recarbrio is indicated for:- treatment of hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap), in adults (see sections 4. 4 og 5. - treatment of bacteraemia that occurs in association with, or is suspected to be associated with hap or vap, in adults. - treatment of infections due to aerobic gram-negative organisms in adults with limited treatment options (see sections 4. 2, 4. 4 og 5. Íhuga ætti að opinbera leiðsögn á réttri notkun af sýklalyfjum.